vs
NEUROCRINE BIOSCIENCES INC（NBIX）与ROKU, INC（ROKU）财务数据对比。点击上方公司名可切换其他公司
ROKU, INC的季度营收约是NEUROCRINE BIOSCIENCES INC的1.6倍（$1.2B vs $805.5M），NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -2.2%，领先21.3%），NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs -18.3%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $298.4M），过去两年NEUROCRINE BIOSCIENCES INC的营收复合增速更高（25.0% vs 13.6%）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
Roku是美国流媒体技术企业，2002年由安东尼·伍德创立，主营数字媒体播放器、电视硬件生产，流媒体内容分发及平台广告运营。截至2024年覆盖用户达1.45亿，是美国流媒体视频分发领域的市场领导者，业务覆盖澳、加、法、德、英及拉美多国。
NBIX vs ROKU — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $805.5M | $1.2B |
| 净利润 | $153.7M | $-27.4M |
| 毛利率 | 97.8% | 35.6% |
| 营业利润率 | 26.2% | 59.7% |
| 净利率 | 19.1% | -2.2% |
| 营收同比 | 28.3% | -18.3% |
| 净利润同比 | 49.1% | -361.0% |
| 每股收益（稀释后） | $1.49 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $1.2B | ||
| Q4 25 | $805.5M | $1.4B | ||
| Q3 25 | $794.9M | $1.2B | ||
| Q2 25 | $687.5M | $1.1B | ||
| Q1 25 | $572.6M | $1.0B | ||
| Q4 24 | $627.7M | $1.2B | ||
| Q3 24 | $622.1M | $1.1B | ||
| Q2 24 | $590.2M | $968.2M |
| Q1 26 | — | $-27.4M | ||
| Q4 25 | $153.7M | $80.5M | ||
| Q3 25 | $209.5M | $24.8M | ||
| Q2 25 | $107.5M | $10.5M | ||
| Q1 25 | $7.9M | $-27.4M | ||
| Q4 24 | $103.1M | $-35.5M | ||
| Q3 24 | $129.8M | $-9.0M | ||
| Q2 24 | $65.0M | $-34.0M |
| Q1 26 | — | 35.6% | ||
| Q4 25 | 97.8% | 43.5% | ||
| Q3 25 | 98.2% | 43.4% | ||
| Q2 25 | 98.4% | 44.8% | ||
| Q1 25 | 98.4% | 43.6% | ||
| Q4 24 | 98.5% | 42.7% | ||
| Q3 24 | 98.7% | 45.2% | ||
| Q2 24 | 98.4% | 43.9% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | 26.2% | 4.7% | ||
| Q3 25 | 30.1% | 0.8% | ||
| Q2 25 | 21.2% | -2.1% | ||
| Q1 25 | 4.1% | -5.7% | ||
| Q4 24 | 22.6% | -3.3% | ||
| Q3 24 | 29.5% | -3.4% | ||
| Q2 24 | 24.6% | -7.4% |
| Q1 26 | — | -2.2% | ||
| Q4 25 | 19.1% | 5.8% | ||
| Q3 25 | 26.4% | 2.0% | ||
| Q2 25 | 15.6% | 0.9% | ||
| Q1 25 | 1.4% | -2.7% | ||
| Q4 24 | 16.4% | -3.0% | ||
| Q3 24 | 20.9% | -0.9% | ||
| Q2 24 | 11.0% | -3.5% |
| Q1 26 | — | $0.57 | ||
| Q4 25 | $1.49 | $0.55 | ||
| Q3 25 | $2.04 | $0.16 | ||
| Q2 25 | $1.06 | $0.07 | ||
| Q1 25 | $0.08 | $-0.19 | ||
| Q4 24 | $1.00 | $-0.24 | ||
| Q3 24 | $1.24 | $-0.06 | ||
| Q2 24 | $0.63 | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $713.0M | $2.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.3B | $2.7B |
| 总资产 | $4.6B | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $2.4B | ||
| Q4 25 | $713.0M | $2.3B | ||
| Q3 25 | $340.2M | $2.3B | ||
| Q2 25 | $264.0M | $2.3B | ||
| Q1 25 | $194.1M | $2.3B | ||
| Q4 24 | $233.0M | $2.2B | ||
| Q3 24 | $349.1M | $2.1B | ||
| Q2 24 | $139.7M | $2.1B |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $3.3B | $2.7B | ||
| Q3 25 | $3.0B | $2.6B | ||
| Q2 25 | $2.7B | $2.6B | ||
| Q1 25 | $2.5B | $2.5B | ||
| Q4 24 | $2.6B | $2.5B | ||
| Q3 24 | $2.7B | $2.5B | ||
| Q2 24 | $2.5B | $2.4B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $4.6B | $4.4B | ||
| Q3 25 | $4.3B | $4.4B | ||
| Q2 25 | $3.9B | $4.3B | ||
| Q1 25 | $3.7B | $4.2B | ||
| Q4 24 | $3.7B | $4.3B | ||
| Q3 24 | $3.5B | $4.3B | ||
| Q2 24 | $3.3B | $4.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.4M | $199.1M |
| 自由现金流经营现金流 - 资本支出 | $386.0M | $298.4M |
| 自由现金流率自由现金流/营收 | 47.9% | 23.9% |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | 2.53× | — |
| 过去12个月自由现金流最近4个季度 | $743.9M | $640.0M |
8季度趋势，按日历期对齐
| Q1 26 | — | $199.1M | ||
| Q4 25 | $388.4M | $107.7M | ||
| Q3 25 | $227.5M | $127.6M | ||
| Q2 25 | $102.0M | $109.7M | ||
| Q1 25 | $64.8M | $138.7M | ||
| Q4 24 | $242.5M | $79.3M | ||
| Q3 24 | $158.0M | $68.7M | ||
| Q2 24 | $64.6M | $23.4M |
| Q1 26 | — | $298.4M | ||
| Q4 25 | $386.0M | $106.6M | ||
| Q3 25 | $214.3M | $126.5M | ||
| Q2 25 | $89.5M | $108.6M | ||
| Q1 25 | $54.1M | $136.8M | ||
| Q4 24 | $235.2M | $76.8M | ||
| Q3 24 | $149.9M | $67.6M | ||
| Q2 24 | $53.0M | $22.5M |
| Q1 26 | — | 23.9% | ||
| Q4 25 | 47.9% | 7.6% | ||
| Q3 25 | 27.0% | 10.4% | ||
| Q2 25 | 13.0% | 9.8% | ||
| Q1 25 | 9.4% | 13.4% | ||
| Q4 24 | 37.5% | 6.4% | ||
| Q3 24 | 24.1% | 6.4% | ||
| Q2 24 | 9.0% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 0.1% | ||
| Q3 25 | 1.7% | 0.1% | ||
| Q2 25 | 1.8% | 0.1% | ||
| Q1 25 | 1.9% | 0.2% | ||
| Q4 24 | 1.2% | 0.2% | ||
| Q3 24 | 1.3% | 0.1% | ||
| Q2 24 | 2.0% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 2.53× | 1.34× | ||
| Q3 25 | 1.09× | 5.14× | ||
| Q2 25 | 0.95× | 10.45× | ||
| Q1 25 | 8.20× | — | ||
| Q4 24 | 2.35× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 0.99× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
ROKU
| Advertising | $612.7M | 49% |
| Subscriptions | $518.5M | 42% |
| Devices | $117.6M | 9% |
